Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | ACSL1 | P33121 | 3/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.46 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.46 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188580 | 0.90 | FFAR4 (0.52) | AKR1C3AKR1C1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1749499 | 0.89 | ACSL1 (0.56) | AKR1C3AKR1C1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10455781 | 0.88 | ELANE (0.57) | AKR1C3AKR1C1ACSL1FFAR4ACSL3 | |
| SCHEMBL795203 | 0.87 | SLC6A4 (0.52) | AKR1C3AKR1C1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26857966 | 0.86 | SLC6A2 (0.46) | SLC6A4SLC6A2SLC6A3ACSL1FFAR4 | |
| SCHEMBL11644936 | 0.85 | FFAR4 (0.45) | AKR1C3AKR1C1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL16112493 | 0.83 | KDM1A (0.49) | SLC6A4SLC6A2SLC6A3FFAR4HRH1 | |
| SCHEMBL11645611 | 0.83 | FFAR4 (0.44) | SLC6A4SLC6A2SLC6A3FFAR4HRH1 | |
| SCHEMBL10454525 | 0.81 | KMT2A (0.53) | AKR1C3AKR1C1ACSL1ACSL3ACSL6 | |
| SCHEMBL6932018 | 0.80 | FFAR4 (0.49) | SLC6A4SLC6A2SLC6A3FFAR4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | AKR1C3 4583/4885AKR1C1 4566/4885SLC6A4 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.